Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05391841
Other study ID # AAG-O-H-2123
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date May 31, 2024
Est. completion date May 2032

Study information

Verified date November 2023
Source Tetec AG
Contact Silvia Rombach, Dr.
Phone +49 7121 1626 202
Email silvia.rombach@tetec-ag.de
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The study is a prospective, multicenter, single-arm non-interventional study to evaluate the efficacy, safety and health economics of NOVOCART® Inject in the treatment of cartilage defects of the knee in pediatric patients with radiologically proven closed epiphyseal growth plates.


Description:

In this non-interventional study NOVOCART® Inject, which is marketed in Germany under a license according to Section 4b of the AMG, will be used in routine clinical practice according to the current authorized Summary of Product Characteristics (SmPC). As stated in this SmPC, NOVOCART® Inject may only be used by physicians who are trained on the product. The treatment with NOVOCART® Inject requires two surgeries. During the first surgery cartilage tissue will be harvested arthroscopically and sent to TETEC AG for NOVOCART® Inject manufacturing, then NOVOCART® Inject will be transplanted during a second surgery about 3 to 4 weeks later. All patients will be followed up for 5 years post NOVOCART® Inject implantation and data will be collected preoperatively and at 3, 6, 12, 18, 24, 36, 48 and 60 months as outlined at the end of this synopsis. NOVOCART® Inject post treatment rehabilitation should follow the recommendations given in the SmPC and during product training. The primary and secondary variables (see below) will be assessed after a follow-up of 24 month post NOVOCART® Inject implantation (primary analysis). Long-term data will be assessed after an additional 3 years follow-up (follow-up analysis). The collected data will be documented using dedicated case report forms (CRFs) which are created by TETEC AG.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date May 2032
Est. primary completion date May 2029
Accepts healthy volunteers No
Gender All
Age group N/A to 17 Years
Eligibility Inclusion Criteria: - Pediatric patients (< 18 years of age at implantation) - Closure of the epiphysis adjacent to the biopsy harvest site or the defect to be treated confirmed by an adequate imaging modality - Localized full-thickness cartilage defect (ICRS grade III or IV) of the knee - Medicinal indication for NOVOCART® Inject treatment Exclusion Criteria: see NOVOCART Inject SmPC

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
NOVOCART Inject
Autologous Chondrocyte Implantation

Locations

Country Name City State
Germany St. Josefs-Hospital Cloppenburg gemeinnützige GmbH Cloppenburg
Germany Universitätsklinikum Freiburg Freiburg
Germany Klinikum rechts der Isar, Technische Universität München München
Germany OCM Klinik GmbH München München
Germany Universitätsklinikum Regensburg Regensburg
Germany Universitätsklinikum Tübingen Tübingen

Sponsors (2)

Lead Sponsor Collaborator
Tetec AG Winicker Norimed GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Adverse reactions Continuous assessment of adverse reactions (ARs) 24-months Follow up, 60-months Follow-up
Other Number of device deficiencies - trephine Number of device deficiencies - trephine 24-months Follow up, 60-months Follow-up
Other Number of device deficiencies - Application System Number of device deficiencies - Application System 24-months Follow up, 60-months Follow-up
Other Number of device deficiencies - number of product related issues Number of device deficiencies - number of product related issues 24-months Follow up, 60-months Follow-up
Primary Responder rate of overall KOOS The overall Knee injury and Osteoarthritis Outcome Score (KOOS5) responder rate defined as the proportion of patients with = 10 points improvement in the KOOS5 from baseline. 24-months Follow-up
Secondary Change of overall KOOS from baseline Change of overall KOOS from baseline to the 24-month assessment, Knee Injury and Osteoarthritis Outcome Score, score 0-100, higher score shows better outcome 24-months Follow-up
Secondary Change of the 5 sub-scores of the KOOS from baseline Change of the 5 sub-scores of the KOOS from baseline to the 24-month assessment, Knee Injury and Osteoarthritis Outcome Score, score 0-100, higher score shows better outcome 24-months Follow-up
Secondary Change of the IKDC subjective score from baseline Change from baseline to the 24-month visit in the IKDC subjective score, international knee documentation committee, score 0-100, higher score shows better outcome 24-months Follow-up
Secondary Change in the IKDC surgeon's part from baseline Change from baseline to the 24-month visit in the IKDC surgeon's part. international knee documentation committee, score 0-100, higher score shows better outcome 24-months Follow-up
Secondary MOCART (MRI imaging) In vivo performance measured by the assessment of the Magnetic Resonance, Observation of Cartilage Repair Tissue (MOCART) score, Magnetic Resonance Observation of Cartilage Repair Tissue, score 0-100, higher score shows better outcome 24-months Follow-up
Secondary IKDC subjective score responder rate IKDC subjective score responder rate, defined as the proportion of patients with > 20.5 points improvement in the IKDC subjective score from baseline to the 24-month visit 24-months Follow-up
Secondary Proportion of patients with treatment failure Proportion of patients with treatment failure 24-months Follow up, 60-months Follow-up
Secondary Number of postop physical therapy Number of postop physical therapy 24-months Follow up, 60-months Follow-up
Secondary Number of postop doctor visits Number of postop doctor visits 24-months Follow up, 60-months Follow-up
Secondary Days of hospitalisation Days of hospitalisation 24-months Follow up, 60-months Follow-up
Secondary Work/school status checklist Work/school status, changes due to injury in work or school status (pupil, worker full or part time, not working, job seeking) 24-months Follow up, 60-months Follow-up
Secondary Days of work/school missed Days of work/school missed 24-months Follow up, 60-months Follow-up
Secondary Patient satisfaction Patient questionnaire, 4 questions with 3 answer choices better, same, worse 24-months Follow up, 60-months Follow-up
Secondary Treatment-related adverse reactions (ARs) Treatment-related adverse reactions (ARs) 24-months Follow up, 60-months Follow-up
Secondary Rate of unplanned re-operations Rate of unplanned re-operations: all unplanned reoperations and those related to NOVOCART® Inject treatment 24-months Follow up, 60-months Follow-up
Secondary Surgical time cut-to-suture time 24-months Follow up, 60-months Follow-up
Secondary Length of incision Length of incision 24-months Follow up, 60-months Follow-up
See also
  Status Clinical Trial Phase
Recruiting NCT02991300 - BioPoly® RS Partial Resurfacing Patella Registry Study
Withdrawn NCT00961597 - Assessment of Outcome of Meniscus Repair With or Without Platelet Rich Plasma N/A
Recruiting NCT04785092 - All Autologous Cartilage Regeneration in the Treatment of the Knee Cartilage Defects N/A
Completed NCT02941120 - Non-interventional Study With NOVOCART® Inject in the Reconstruction of the Knee Cartilage Defects
Completed NCT02179346 - Observational Study With NOVOCART® Inject in the Reconstruction of the Hip Joint With Full Thickness Cartilage Defects
Recruiting NCT04537013 - Clinical Study of Chondro-Gide® for Large Chondral Lesions in the Knee N/A
Not yet recruiting NCT06238947 - Long-term Outcome Evaluation of Patients Undergoing Autologous Chondrocyte Transplantation Delivered on Biomaterial
Active, not recruiting NCT04186208 - Non-interventional Study With NOVOCART® 3D for the Treatment of Cartilage Defects of the Knee in Pediatric Patients